Triple therapy shows strong response in BRAF V600E mutant metastatic colorectal cancer
- First-Line treatment with Encorafenib, Cetuximab, and mFOLFOX6 chemotherapy showed a 60.9% overall response rate in BRAF V600E-mutant metastatic colorectal cancer, compared to 40% with standard of care chemotherapy, according to the BREAKWATER trial.
- The median duration of response was 13.9 months for EC-FOLFOX6, while it was 11.1 months for standard of care, as reported by Scott Kopetz, MD, PhD.
- The BREAKWATER trial results led to FDA approval in 2024 for the new treatment regimen in first-line settings for BRAF V600E-mutant metastatic colorectal cancer.
- Kopetz stated that the study supports EC and FOLFOX as a new standard of care, indicating a significant improvement in response rates for this challenging patient population.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left0Leaning Right1Center4Last UpdatedBias Distribution80% Center
Bias Distribution
- 80% of the sources are Center
80% Center
C 80%
R 20%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
